Stock Track | Natera Soars 13.05% in Post-Market Trading on Q2 Earnings Beat and Raised Revenue Guidance

Stock Track08-07

Natera (NTRA) shares surged 13.05% in post-market trading Thursday, after the genetic testing company reported second-quarter financial results that significantly exceeded analyst expectations and raised its full-year revenue forecast.

The company posted Q2 revenue of $752.8 million, a 37.7% increase year-over-year, well above the consensus estimate of $660.7 million. Adjusted loss per share narrowed to $0.47, beating the expected loss of $0.49. Natera also lifted its 2026 revenue guidance to a range of $2.85 billion to $2.91 billion, up from the prior $2.74 billion to $2.82 billion and above the FactSet consensus of $2.80 billion. The strong performance was driven by higher overall test volumes, with oncology test volumes surging 57% year-over-year.

Management attributed the improved results to robust demand for its Signatera molecular residual disease test and continued progress in reducing cost of revenues. The company also provided an outlook for positive cash flow in 2026, reinforcing investor confidence in its growth trajectory.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1177338406?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-07 08:16","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1177338406","market":"nz","top_or_hot":-1,"title":"Stock Track | Natera Soars 13.05% in Post-Market Trading on Q2 Earnings Beat and Raised Revenue Guidance","media":"Stock Track","content":"<p>Natera (NTRA) shares surged 13.05% in post-market trading Thursday, after the genetic testing company reported second-quarter financial results that significantly exceeded analyst expectations and raised its full-year revenue forecast.</p><p>The company posted Q2 revenue of $752.8 million, a 37.7% increase year-over-year, well above the consensus estimate of $660.7 million. Adjusted loss per share narrowed to $0.47, beating the expected loss of $0.49. Natera also lifted its 2026 revenue guidance to a range of $2.85 billion to $2.91 billion, up from the prior $2.74 billion to $2.82 billion and above the FactSet consensus of $2.80 billion. The strong performance was driven by higher overall test volumes, with oncology test volumes surging 57% year-over-year.</p><p>Management attributed the improved results to robust demand for its Signatera molecular residual disease test and continued progress in reducing cost of revenues. The company also provided an outlook for positive cash flow in 2026, reinforcing investor confidence in its growth trajectory.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Natera Soars 13.05% in Post-Market Trading on Q2 Earnings Beat and Raised Revenue Guidance</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Natera Soars 13.05% in Post-Market Trading on Q2 Earnings Beat and Raised Revenue Guidance\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-08-07 08:16</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Natera (NTRA) shares surged 13.05% in post-market trading Thursday, after the genetic testing company reported second-quarter financial results that significantly exceeded analyst expectations and raised its full-year revenue forecast.</p><p>The company posted Q2 revenue of $752.8 million, a 37.7% increase year-over-year, well above the consensus estimate of $660.7 million. Adjusted loss per share narrowed to $0.47, beating the expected loss of $0.49. Natera also lifted its 2026 revenue guidance to a range of $2.85 billion to $2.91 billion, up from the prior $2.74 billion to $2.82 billion and above the FactSet consensus of $2.80 billion. The strong performance was driven by higher overall test volumes, with oncology test volumes surging 57% year-over-year.</p><p>Management attributed the improved results to robust demand for its Signatera molecular residual disease test and continued progress in reducing cost of revenues. The company also provided an outlook for positive cash flow in 2026, reinforcing investor confidence in its growth trajectory.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NTRA","symbol_name":"Natera, Inc.","start_time":0,"source_url":"","article_id":"1177338406","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1177338406","pubTimestamp":1786061811,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Natera (NTRA) shares surged 13.05% in post-market trading Thursday, after the genetic testing company reported second-quarter financial results that significantly exceeded analyst expectations and...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"NTRA":"Natera, Inc."},"translate_title":"股票跟踪 | Natera 因第二季度盈利超出预期并上调收入指引，在盘后交易中飙升 13.05%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NTRA":1},"content_text":"Natera (NTRA) shares surged 13.05% in post-market trading Thursday, after the genetic testing company reported second-quarter financial results that significantly exceeded analyst expectations and raised its full-year revenue forecast.The company posted Q2 revenue of $752.8 million, a 37.7% increase year-over-year, well above the consensus estimate of $660.7 million. Adjusted loss per share narrowed to $0.47, beating the expected loss of $0.49. Natera also lifted its 2026 revenue guidance to a range of $2.85 billion to $2.91 billion, up from the prior $2.74 billion to $2.82 billion and above the FactSet consensus of $2.80 billion. The strong performance was driven by higher overall test volumes, with oncology test volumes surging 57% year-over-year.Management attributed the improved results to robust demand for its Signatera molecular residual disease test and continued progress in reducing cost of revenues. The company also provided an outlook for positive cash flow in 2026, reinforcing investor confidence in its growth trajectory.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"2","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1177338406","isCrawlerRequest":true}